GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
14 août 2024 16h05 HE
|
GT Biopharma, Inc.
GTB-3650 TriKE® Phase 1 trial initiation expected in 2H 2024; initial clinical data expected in 1H 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in 1H...
GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
14 août 2024 08h05 HE
|
GRI Bio, Inc.
Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and...
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
01 août 2024 07h30 HE
|
Arbutus Biopharma Corporation
End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen IM-PROVE I...
Aridis Provides Corporate Update
24 juin 2024 17h58 HE
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent...
Mise à jour corporative de Kintavar
29 mai 2024 07h43 HE
|
Kintavar Exploration inc.
MONTRÉAL, 29 mai 2024 (GLOBE NEWSWIRE) -- Kintavar Exploration Inc. (la « Société » ou « Kintavar ») (TSX-V : KTR), est heureuse de fournir une mise à jour corporative détaillant les objectifs...
Kintavar Corporate Update
29 mai 2024 07h43 HE
|
Kintavar Explorations Inc.
MONTREAL, May 29, 2024 (GLOBE NEWSWIRE) -- Kintavar Exploration Inc. (the “Corporation” or “Kintavar”) (TSX-V: KTR), is pleased to provide a corporate update detailing the Corporations objectives...
Odysight.ai Announces First Quarter 2024 Financial Results and Provides Corporate Update
16 mai 2024 08h30 HE
|
Odysight.ai Inc.
OMER, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (OTCQB: ODYS), a leading provider of visual based predictive maintenance (PdM) and condition-based monitoring (CBM) solutions,...
Optimi Health Provides Corporate Update
10 mai 2024 08h50 HE
|
Optimi Health Corp.
Optimi Health provides corporate update.
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
02 mai 2024 07h30 HE
|
Arbutus Biopharma Corporation
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001...
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
25 avr. 2024 08h35 HE
|
NurExone Biologic Inc
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility